P66 Acute stenting and concomitant tirofiban administration for acute intracranial artery dissections. (29th August 2022)

• Record Type: Journal Article
• Authors: Bernava, G; Meling, TR; Rosi, A; Hofmeister, J; Yilmaz, H; Carrera, E; Lovblad, K-O; Kulcsar, Z; Machi, P
• Is Part Of: Journal of neurointerventional surgery. Volume 14(2022)Supplement 2
• Page Start: A35
• Page End: A35
• Publication Date: 2022-08-29
• Subjects: Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2022-ESMINT.87
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Introduction: Intracranial artery dissection is an uncommon and often underdiagnosed cause of acute ischemic stroke. Despite the fact that acute stenting of the dissected arterial segment is a therapeutic option, the associated antiplatelet therapy and the timing of endovascular treatment remain a matter of debate. Aim of study: To evaluate through our clinical experience the efficacy and safety of acute intracranial stenting in association with concomitant intravenous tirofiban administration. Methods: A retrospective single-center study of the clinical and radiological records of all patients treated at our institution with intracranial stenting in the setting of acute ischemic stroke between January 2010 and April 2022 was performed. Results: Eight patients with intracranial artery dissection underwent acute stenting with concomitant administration of tirofiban during the study period. Medium-term follow-up showed patency of the parent artery in 7/8 cases (87.5%). The modified Rankin Score was 0–2 at 3 months in 6/8 cases (75%). Conclusions: Acute intracranial stenting together with intravenous tirofiban as first-line treatment could be a viable therapeutic approach in patients with intracranial artery dissection. References: J Neurosurg Pediatr 2010;6 (2):154–8. DOI: 10.3171/2010.4. Peds1081 Lancet Neurol 2015;14 (6):640–54. DOI: 10.1016/S1474-4422(15)00009-5 Clin Neurol Neurosurg 2020;190:105653. DOI: 10.1016/J. Clineuro.2019.10565 Eur J Neurol 2014;21 (6):820–6. Doi: 10.1111/Ene.12384 J Neurointerv Surg 2018;10 (8):761–64. DOI: 10.1136/Neurintsurg-2018-013763 Neurosurgery 2015;76 (2):158–64; Discussion 64. DOI: 10.1227/Neu.0000000000000582 Ajnr AM J Neuroradiol 2010;31 (8):1529–32. DOI: 10.3174/Ajnr.A2115 Stroke 2005;36 (9):E80–2. DOI: 10.1161/01.Str.0000177883.50262.Cf Circulation 1997;96 (5):1445–53. DOI: 10.1161/01.Cir.96.5.1445 Circulation 2001;103 (21):2572–8. DOI: 10.1161/01.Cir.103.21.2572 Clin Neuroradiol 2019;29 (3):445–57. DOI: 10.1007/S00062-018-0690-4 Stroke 2013;44 (1):126–31. DOI: 10.1161/Strokeaha.112.670745 J Neurointerv Surg 2015;7 (1):8–15. DOI: 10.1136/Neurintsurg-2013-011004 Lancet Neurol 2013;12 (7):677–88. DOI: 10.1016/S1474-4422(13)70101-7 Ajnr Am J Neuroradiol 2016;37 (3):508–14. DOI: 10.3174/Ajnr.A4551 Neurosurgery 2019;85 (6):E1037-E42. DOI: 10.1093/Neuros/Nyz226 J Neurointerv Surg 2016;8 (11):1148–53. DOI: 10.1136/Neurintsurg-2015-012055 Neurosurgery 2018;82 (3):268–77. DOI: 10.1093/Neuros/Nyx170 Stroke 2016;47 (9):2360–3. DOI: 10.1161/Strokeaha.116.014073 Ajnr Am J Neuroradiol 2018;39 (2):331–36. DOI: 10.3174/Ajnr.A5477 Drugs 2019;79 (5):515–29. DOI: 10.1007/S40265-019-01078-0 Cardiovasc Intervent Radiol 2019;42 (6):863–72. DOI: 10.1007/S00270-019-02187-9 Ajnr AM J Neuroradiol 2015;36 (10):1947–52. DOI: 10.3174/Ajnr.A4364 Do you have any conflict of interest to declare? : No